These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 36587500)

  • 1. Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors.
    Yan T; Yu L; Shangguan D; Li W; Liu N; Chen Y; Fu Y; Tang J; Liao D
    Int Immunopharmacol; 2023 Feb; 115():109638. PubMed ID: 36587500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1 
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis].
    Sheng J; Yu X; Li H; Fan Y
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):976-982. PubMed ID: 32773010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.
    Twomey JD; Zhang B
    AAPS J; 2021 Mar; 23(2):39. PubMed ID: 33677681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented Antitumor Effect of Unripe
    Lee EJ; Yang JH; Choi JG; Chung HS
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus Silica Nanoparticle-Based Tumor Microenvironment Modulator for Restoring Tumor Sensitivity to Programmed Cell Death Ligand 1 Immune Checkpoint Blockade Therapy.
    Lin X; Li F; Guan J; Wang X; Yao C; Zeng Y; Liu X
    ACS Nano; 2023 Aug; 17(15):14494-14507. PubMed ID: 37485850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors.
    Han L; Meng Y; Jianguo Z
    Curr Cancer Drug Targets; 2024; 24(11):1104-1115. PubMed ID: 38318829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
    Liao L; Xu H; Zhao Y; Zheng X
    Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
    Naimi A; Mohammed RN; Raji A; Chupradit S; Yumashev AV; Suksatan W; Shalaby MN; Thangavelu L; Kamrava S; Shomali N; Sohrabi AD; Adili A; Noroozi-Aghideh A; Razeghian E
    Cell Commun Signal; 2022 Apr; 20(1):44. PubMed ID: 35392976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
    Tang Q; Li S; Huang G; Liu H
    Int Immunopharmacol; 2023 Jun; 119():110158. PubMed ID: 37062259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities.
    Peng Z; Li M; Li H; Gao Q
    Drug Discov Today; 2023 Aug; 28(8):103666. PubMed ID: 37302543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer.
    AmeliMojarad M; AmeliMojarad M; Cui X
    Pathol Res Pract; 2023 Apr; 244():154338. PubMed ID: 36905697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research Advances of Immunotherapy of Exosome PD-L1 
in Non-small Cell Lung Cancer].
    Wang N; Song X
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):689-695. PubMed ID: 36172735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.